ClinicalTrials.gg
RecruitingNCT05832489ImAteM-TDAUpdated Aug 21, 2026

EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders

A Phase 3 interventional study of Placebo and Methylphenidate immediate release 25mg in Adult ADHD and Adult-onset ADHD With Mood Disorder, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by University Hospital, Strasbourg, France · Phase 3, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France — 20 open to participants now, 20 under way, 2 of them phase 3. Attention Deficit Disorder with Hyperactivity · France.

Planned enrollment
30th of 60
80 · median 80
Started
2024
with 3 others
Phase 3
14 of 82
2 open now
Primary completion
2027-05
later than 8 of 19 live
Registered
63rd of 82
by date
Lead sponsor
8 of 82
University Hospital, Strasbourg, France

Among the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, this one is the 30th largest by planned enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2024, is one of 14 in phase 3, reaches primary completion later than 8 of the 19 other live ones, and was the 63rd registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

20 of the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, or all of them as a file.
02

Study summary

Attention Deficit Hyperactivity Disorder (ADHD) in adults is a common psychiatric disorder, with important consequences in terms of quality of life, mental health (associated disorders and poorer response to treatment), family life, risk of accidents; with a consequent cost for society.

Adult ADHD is frequently associated with psychiatric co-morbidities, and notably associated with mood disorders (major depressive disorder or bipolar disorder) in about 50% of cases.

The diagnosis of ADHD in adults is made in patients with an attentional complaint (pure ADHD or ADHD-P), but also very often in the management of a comorbid mood disorder (ADHD associated with mood disorder, or ADHD-MD). In this case, the ADHD had no impact during childhood and adolescence.

Medication management is well established for ADHD-P, and medication is based on methylphenidate, which has a rapid and significant effect on attentional symptoms and impulsivity. However, in the case of ADHD-HD, there is little evidence of treatment efficacy and the mechanisms of action of methylphenidate at the brain level are poorly understood.

The aim of the study is to determine the neural mechanisms of the effect of methylphenidate, using functional MRI and EEG, in ADHD-P and ADHD-HD patients, and to compare them to healthy subjects. A single dose allows us to observe effects that are then persistent with repeated doses. The aim is to determine, by means of a biomarker, whether methylphenidate treatment responds to the same mechanisms in the different groups and would be relevant in ADHD-P as in ADHD-HD.

Main objective:

To determine whether methylphenidate impacts differently on brain circuits associated with cognitive functions in the two clinical populations studied (adult ADHD patients and patients with post mood disorder attentional deficit) and in comparison to controls.

Secondary objectives:

  1. To determine the effect of methylphenidate on baseline brain flow in the two clinical populations and in controls (healthy subjects).
  2. To determine whether methylphenidate has a different impact on cognitive performance in the two clinical populations studied and in comparison to controls (healthy subjects).
  3. To confirm the effect of methylphenidate on the maintenance of cortical arousal.
  4. To distinguish the brain networks impacted by methylphenidate (maintenance of attention or inhibition) with MRI and EEG.
Read the detailed description

It is a cross-over, randomized, controlled, double-blind, study. 3 groups of 20 subjects are constituted: A: adult patients with ADHD (ADHD-P) B: patients with attention deficit due to/emphasized by mood disorders (ADHD-HD) C: healthy control population

During the inclusion visit the subjects fill in self-questionnaires (ASRS, WURS, WRAADDS, WFIRFS, TEMPS-A, BDI, BAI, RCTQ, mind-wandering). A 45-minute neuropsychological assessment will be carried out by a neuropsychologist, followed by training in the cognitive tasks used during the experimental sessions.

During imaging session 1 (3 to 60 days from inclusion):

Patients usually taking methylphenidate will discontinue methylphenidate treatment two days the imaging session.

Subject takes treatment (or placebo) 30-60 minutes before MRI. The MRI is performed at rest and associated with cognitive tasks (SART) (65 minutes duration). EEG is performed after in combination with a cognitive task (SART) (duration 40 minutes). Finally subjects complete self-questionnaires.

During imaging session 2 (14 to 90 days from inclusion): the same procedure is done again.

Patients usually taking methylphenidate will discontinue methylphenidate treatment two days before the session.

Subject takes placebo (if treatment during imaging session 1) or treatment (if placebo during imaging session 1) 30-60 minutes before MRI. MRI and EEG procedure are the same.

fMRI imaging includes rest and imaging during SART task (Go-NoGo), using BOLD and ASL sequences. EEG is performed during SART task.

03

Conditions studied

  • Adult ADHD
  • Adult-onset ADHD With Mood Disorder

Keywords

  • Adult ADHD
  • Sustained attention
  • fMRI
  • EEG
  • Pharmacoimaging
  • Methylphenidate
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject (male or female) aged 18 to 60 years old
  • Subject affiliated to a social protection health insurance scheme
  • Subject capable of understanding the objectives and risks of the research and of providing dated and signed
  • Subject having been informed of the results of the prior medical examination
  • For a woman of childbearing age: negative blood pregnancy test and effective throughout the study (intrauterine device, sterilization, estro-progestogen or progestogen per os, injectable or in the form of an implant or ring) and refusal to perform a pregnancy test before each MRI)

Inclusion criteria for Group A: ADHD patients without associated mood disorder (ADHD-P)

  • Diagnosis of ADHD according to (in particular criterion B: presence of symptoms before the age of 12 years) NB: the diagnosis was not necessarily made at this age.
  • Subject with or without methylphenidate treatment

Inclusion criteria for Group B: Patients with attention deficit disorder due to/accentuated by mood disorders (ADHD-MD)

  • Association of ADHD symptoms with attentional disorders according to the combination of the following criteria :
  • Diagnosis of Recurrent Depressive Disorder or Bipolar Disorder according to DSM-5
  • Currently euthymic, i.e. a QIDS-16SC depression score \< 6 and a YRMS mania score \< 6, and clinically stabilized for at least 6 weeks prior to inclusion (stable and off-acute treatment). NB: for ISQ item 10 (concentration/decision making, score decision making only)
  • DSM-5 Adult ADHD Criteria A (at least 5 symptoms of inattention and/or hyperactivity/impulsivity)
  • Absence of Criterion D during childhood, adolescence and before mood disorders (i.e., no significant impact with reduced quality of social, academic or occupational functioning)
  • Presence of Criterion D at present (symptoms have a significant impact with a reduction in the quality of social, academic or professional functioning)
  • Subject with or without approved mood disorder treatment: Mood stabilizers (lithium, valproate, lamotrigine); antidepressants (SSRIs, IRSNa ≤60mg/j of venlafaxine and ≤60mg/j of duloxetine); benzodiazepines in stable doses for more than a month.
  • Subject with or without methylphenidate treatment

Inclusion criteria for Group C: healthy subjects control

- Subject with no psychiatric or neurological history

Exclusion criteria

Exclusion criteria common to all groups

  • Subjects with to methylphenidate :

    • to the active substance,
    • glaucoma,
    • pheochromocytoma,
    • treatment with other indirect sympathomimetics or alpha sympathomimetics (oral and/or nasal routes), irreversible MAOIs
    • Hyperthyroidism or thyrotoxicosis,
    • Pre-existing cardiovascular disorders including severe hypertension, heart failure, occlusive arterial disease, angina pectoris, congenital heart disease with hemodynamic impact, cardiomyopathy, myocardial infarction, arrhythmias and potentially life-threatening ductopathies (disorders caused by ion channel dysfunction),
    • Pre-existing cerebrovascular disorders, brain aneurysms, vascular abnormalities including vasculitis or stroke,
    • wheat allergy (other than celiac disease)
  • Diagnosis or history of severe depression, anorexia nervosa or anorexic disorder, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic or borderline personality disorder.
  • Diagnosis or history of episodic and severe (type 1) (and poorly controlled) bipolar (affective) disorder.
  • Subjectis with contraindication to performing an MRI: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular shunt
  • History that may affect brain anatomy or be related to an abnormality (neonatal suffering, neurosurgical operation, comitiality, stroke, head injury with unconsciousness of more than 15 minutes and mental retardation)
  • History that may affect brain function (general anaesthesia or ECT within 3 months prior to inclusion)
  • Substance Use Disorder as per criteria (except tobacco)
  • Pregnant women or, in women of childbearing age and ability (non-sterile), lack of effective
  • Breastfeeding women
  • Severe or unstable somatic pathology.
  • Subject deprived of liberty, or in care under restraint
  • Subject under safeguard of justice
  • Incompetent subject (subject to a legal protection measure: curatorship, guardianship, future protection mandate, family habilitation)
  • Impossibility to give informed information about the subject (subject in an emergency situation, difficulties in understanding the subject, ...)
  • Subject in exclusion period defined by another protocol in progress

Exclusion criteria for Group A: ADHD patients without associated mood disorder (ADHD-P)

  • Current Mood Disorder
  • History of bipolar disorder in a first-degree relative
  • Taking unauthorized psychotropic drugs: all antidepressants, antipsychotics, sedative antihistamines, regular hypnotics, benzodiazepines in unstable doses.

Exclusion criteria for Group B: Patients with attention deficit disorder due to/accentuated by mood disorders (ADHD-MD)

  • Acute phase of mood disorder defined by scores a depression score in the QIDS-16SC ≥ 6 and a mania score in the YRMS ≥ 6. NB: for ISQ item 10 (concentration/decision making, score decision making only).
  • Use of unauthorized psychotropic drugs including antipsychotics, sedative antihistamines, high-dose IRSNa (>150mg/d venlafaxine and >60mg/d duloxetine), MAOIs, tricyclic antidepressants, benzodiazepines in unstable doses.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Group A

    Adult patients with ADHD (ADHD-P) receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)

    Drug: Placebo · Drug: Methylphenidate immediate release 25mg

  • Experimental
    Group B

    Adult patients with attention deficit due to/emphasized by mood disorders (ADHD-HD) receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)

    Drug: Placebo · Drug: Methylphenidate immediate release 25mg

  • Experimental
    Group C

    Adult Healthy controls receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)

    Drug: Placebo · Drug: Methylphenidate immediate release 25mg

Interventions

  • DrugPlacebo

    Patients will have 2 imaging sessions (MRI and EEG) after either: * methylphenidate immediate release 25 mg * placebo in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.

    Also known as: MRI, EEG

  • DrugMethylphenidate immediate release 25mg

    Patients will have 2 imaging sessions (MRI and EEG) after either: * methylphenidate immediate release 25 mg * placebo in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.

    Also known as: MRI, EEG

06

What researchers measure

Primary outcomes

  1. Effect of methylphenidate on the task vs. rest activation differential (treatment x group interaction) in a region defined by its involvement in the cognitive task and its responsiveness to methylphenidate.

    Changes in brain activations from J3-J600 to J14-J90 (MRI) in ADHD patients (ADHD-P and ADHD-HD), compared to healthy subjects(ADHD-P and ADHD-HD), compared to healthy subjects\] ROI (Region of Interest) analysis to maximize power.

    Time frame: 2 hours after intake of methylphenidate or placebo

Secondary outcomes

  1. Decrease in rCBF (regional Cerebral Blood Flow) in the methylphenidate vs. placebo condition, in the different groups (group x treatment interaction).

    Time frame: 2 hours after intake of methylphenidate or placebo

  2. Improved cognitive performance in sustained attention and inhibition tasks (SART : number of errors) following methylphenidate administration, in the different groups.

    Time frame: 2 hours after intake of methylphenidate or placebo

  3. EEG spectrum power in the low frequencies (proportion of delta power (1-4Hz) and theta power EEG bands (4-8Hz)) in the methylphenidate vs. placebo condition

    Time frame: 3 hours after intake of methylphenidate or placebo

  4. MRI: Interaction group x treatment x task on brain activation related to sustained attention and inhibition corresponding to each of these tasks.

    Time frame: 2 hours after intake of methylphenidate or placebo

  5. EEG evoked potentials: Interaction group x treatment x task on the amplitude of the P300 wave related to sustained attention (P300b) and related to inhibition (P300a) corresponding to each of these tasks.

    Time frame: 3 hours after intake of methylphenidate or placebo

07

Study locations

1 of 1 sites recruiting
  • Service de Psychiatrie 2, Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
    Recruiting
    • Sébastien WEIBEL, MD · Contactsebastien.weibel@chru-strasbourg.fr · 33388115157
    • Sébastien WEIBEL, MD · Principal investigator
    • Jack FOUCHER, MD · Sub investigator
    • Gilles BERTSCHY, MD · Sub investigator
    • Catherine MUTTER, MD · Sub investigator
    • Renaud FELTEN, MD · Sub investigator
    • Clémence RISSER, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for May 2027, 39 months after the start.

Of 80 phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 32. This study's planned 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2022
First posted
Apr 27, 2023
StartActual
Feb 26, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05832489
Responsible party
Sponsor
First posted
Apr 27, 2023
Start date
Feb 26, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Sébastien WEIBEL, MD
Contact
sebastien.weibel@chru-strasbourg.fr
33388115157
Hélène SOAVELO
Contact
helene.soavelo@chru-strasbourg.fr
33388116559
Sébastien WEIBEL, MD
principal investigator · Hôpitaux Universitaires de Strasbourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion